Neuropace (NPCE)

• Market cap: $427M
• 1 day: 6.75%
• 5 days: 8.25%
• 1 month: 11.09%
• 3 months: 13.30%
• 6 months: 90.70%
• Year to date: 13.30%
• 1 year: -4.09%
• 5 years: -47.44%
• 10 years: -47.44%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2,500% more call options, than puts

Call options by funds: $260K | Put options by funds: $10K

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

126% more capital invested

Capital invested by funds: $103M [Q3] → $234M (+$130M) [Q4]

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

29% more funds holding

Funds holding: 48 [Q3] → 62 (+14) [Q4]

19.2% more ownership

Funds ownership: 50.71% [Q3] → 69.91% (+19.2%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 30% upside
• Avg. target: $18 37% upside
• High target: $20 52% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target	52% upside $20	Overweight Maintained	5 Mar 2025
Wells Fargo Larry Biegelsen 36% 1-year accuracy 17 / 47 met price target	30% upside $17	Overweight Maintained	30 Jan 2025
UBS Priya Sachdeva 0% 1-year accuracy 0 / 3 met price target	30% upside $17	Buy Initiated	21 Jan 2025